Darunavir is a robust and widely usable drug. Where it does not fit, the reason is usually the booster it requires rather than darunavir itself.
Who should avoid it outright?
Anyone with a documented severe hypersensitivity reaction to darunavir. Anyone taking a medicine contraindicated with boosters, of which there are several. Anyone taking rifampicin or St John's wort, which reduce it enough to make it unreliable.
What about sulfonamide allergy?
Darunavir contains a sulfonamide component. A history of severe reaction to sulfonamide antibiotics is a reason for caution rather than automatic exclusion, since cross-reactivity is not straightforward. It should be discussed rather than assumed either way.
What about liver impairment?
Not recommended in severe hepatic impairment. Mild to moderate impairment does not require adjustment. Anyone with advanced liver disease from hepatitis B or C needs this considered when a regimen is chosen.
What about people on many other medicines?
The group for whom boosted regimens fit least well. Someone taking several cardiac, respiratory or psychiatric medicines faces a cumulative interaction burden that an unboosted regimen simply avoids, and that is a reasonable basis for choosing differently.
What about recreational drug use?
Not a prohibition and a genuine safety consideration. The raised levels of stimulants and ketamine on boosted regimens have caused deaths, and switching to an unboosted regimen is a legitimate clinical reason that clinics take seriously.
What about cardiovascular risk?
Worth weighing. The lipid effects of boosted protease inhibitors contribute over years, and for someone with substantial existing risk an integrase inhibitor may be preferable. This is a discussion rather than a rule.
What about pregnancy?
Darunavir is used in pregnancy, generally boosted with ritonavir and often twice daily, because levels fall in the later stages. Cobicistat-boosted regimens are generally avoided. Raise a pregnancy or a plan for one early so the regimen can be reviewed.
What about existing resistance?
Extensive protease inhibitor resistance may require twice-daily dosing or, occasionally, make darunavir unsuitable. Resistance testing determines this, and it is one of the few drugs that frequently remains active where others do not.
Is it ever the only option?
Rarely, and it is sometimes the best option in a narrow field. For people with extensive resistance across other classes, boosted darunavir combined with newer agents may be what makes a working regimen possible.
What are the alternatives?
Integrase inhibitors such as dolutegravir and bictegravir, which are first-line, unboosted, better tolerated and have high resistance barriers of their own. Atazanavir where a protease inhibitor is wanted and jaundice is acceptable. Doravirine among the non-nucleosides.
Can you switch away easily?
Usually. Switching from a boosted protease inhibitor to an unboosted integrase inhibitor is routine for people who are suppressed, and it typically simplifies the interaction picture considerably.
Who decides?
You do, with a clinician. If the interaction burden, the tablet count or the side effects are making your life difficult, that is a legitimate reason to ask for a change rather than something to absorb.
Is a second opinion reasonable?
Entirely. If you have been told darunavir is your only option, or that you cannot change, asking to discuss it again or to see someone else is a normal part of care rather than a complaint about anyone.
What happens if you have to change?
Switching is routine and suppression is maintained provided the new regimen is fully active. Coming off darunavir is not a setback and it does not narrow your options later, since most changes are reversible.
What should you bring to the conversation?
What is actually bothering you, in concrete terms, and what you would want instead if it were possible. That produces a more useful discussion than a general sense that something is not right.
Does avoiding it limit you later?
Rarely. Not taking darunavir now does not rule it out in future, and it does not narrow the options available to you. Regimens are revisited regularly as circumstances change.